PLUS THERAPEUTICS, INC. (PSTV): Nasdaq/NYSE listing notice — Plus Therapeutics gets Nasdaq delisting notice for negative stockholders' equity

PLUS THERAPEUTICS, INC.

Company reported stockholders' equity deficit of $23.6M as of March 31, 2025, failing Nasdaq's $2.5M minimum.
Nasdaq staff determined to delist securities; company must request a hearing by June 10, 2025.
Common stock (PSTV) continues trading on Nasdaq Capital Market pending hearing decision.
Company plans to appeal; hearing typically scheduled 30-45 days after request.
Previously regained compliance on equity requirement on March 7, 2025, but fell back into non-compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

PLUS THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

June 3, 2025, Plus Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the Rule 5250(c)(1) due to filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”) on May 30, 2025. As previously disclosed, on March 8, 2024, the Company received a written notice from the Staff, notifying the Company that it no longer complied with the requir

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-137089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.